Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.32 |
| ▸ | ESR1 | P03372 | 1/20 | 0.32 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.31 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4241 | 0.75 | ESR1 (0.34) | CYP3A4ESR1ESR2MAPK1NR1H2 | |
| SCHEMBL450654 | 0.75 | TAAR1 (0.36) | CYP3A4CYP2D6ESR1ESR2MAPK1 | |
| SCHEMBL708403 | 0.75 | ESR1 (0.34) | CYP3A4ESR1ESR2MAPK1NR1H2 | |
| SCHEMBL6391397 | 0.73 | ESR1 (0.33) | CYP3A4ESR1ESR2MAPK1NR1H2 | |
| SCHEMBL1314801 | 0.73 | ESR1 (0.38) | ESR1ESR2MAPK1NR1H2NR1H3 | |
| SCHEMBL2492802 | 0.71 | ESR1 (0.32) | CYP3A4ESR1ESR2MAPK1NR1H2 | |
| SCHEMBL9746360 | 0.70 | TP53 (0.33) | CYP2D6ESR1ESR2MAPK1 | |
| SCHEMBL9815122 | 0.70 | ESR1 (0.35) | CYP3A4ESR1ESR2MAPK1NR1H2 | |
| SCHEMBL3526796 | 0.69 | ESR1 (0.37) | CYP3A4CYP2D6ESR1ESR2MAPK1 | |
| SCHEMBL29749402 | 0.69 | ESR1 (0.37) | CYP3A4CYP2D6ESR1ESR2MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090012139-A1 | AMINO-5-[4-(DIFLUOROMETHOXY) PHENYL]-5-PHENYLIMIDAZOLONE COMPOUNDS FOR THE INHIBITION OF BETA-SECRETASE | WYETH (US) | 2009-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012139-A1 | AMINO-5-[4-(DIFLUOROMETHOXY) PHENYL]-5-PHENYLIMIDAZOLONE COMPOUNDS FOR THE INHIBITION OF BETA-SECRETASE | BACE1, BACE2, APP | CYP1A2 4070/4885CYP3A4 3960/4885CYP2D6 4643/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.